G. Dane

1.2k total citations
12 papers, 906 citations indexed

About

G. Dane is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, G. Dane has authored 12 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Epidemiology. Recurrent topics in G. Dane's work include Lung Cancer Research Studies (9 papers), Cancer therapeutics and mechanisms (5 papers) and Neuroendocrine Tumor Research Advances (5 papers). G. Dane is often cited by papers focused on Lung Cancer Research Studies (9 papers), Cancer therapeutics and mechanisms (5 papers) and Neuroendocrine Tumor Research Advances (5 papers). G. Dane collaborates with scholars based in United Kingdom, Germany and Canada. G. Dane's co-authors include Graham Ross, T. Crofts, Yaroslav Shparyk, Nicholas Thatcher, Tudor–Eliade Ciuleanu, Mary O’Brien, Gábor Juhász, Joachim von Pawel, Andrea Ardizzoni and A. Preston and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Pharmacology and European Journal of Cancer.

In The Last Decade

G. Dane

12 papers receiving 869 citations

Peers

G. Dane
Jane Carleton United States
Coralie Williams United States
IE Smith United Kingdom
M K Bowling United States
Peter Mu‐Hsin Chang Taiwan
Karen Zempolich United States
Seng Chuan Tang Netherlands
Fathima Sheriff United States
Jiamao Lin China
Raquel Torres Spain
Jane Carleton United States
G. Dane
Citations per year, relative to G. Dane G. Dane (= 1×) peers Jane Carleton

Countries citing papers authored by G. Dane

Since Specialization
Citations

This map shows the geographic impact of G. Dane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Dane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Dane more than expected).

Fields of papers citing papers by G. Dane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Dane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Dane. The network helps show where G. Dane may publish in the future.

Co-authorship network of co-authors of G. Dane

This figure shows the co-authorship network connecting the top 25 collaborators of G. Dane. A scholar is included among the top collaborators of G. Dane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Dane. G. Dane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Eckardt, John R., Joachim von Pawel, Jean-Louis Pujol, et al.. (2007). Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(15). 2086–2092. 274 indexed citations
2.
O’Brien, Mary, Tudor–Eliade Ciuleanu, Yaroslav Shparyk, et al.. (2006). Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Journal of Clinical Oncology. 24(34). 5441–5447. 449 indexed citations
3.
Ramlau, Rodryg, Radj Gervais, Maciej Krzakowski, et al.. (2006). Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 24(18). 2800–2807. 82 indexed citations
4.
Ramlau, Rodryg, R. Gervais, Maciej Krzakowski, et al.. (2005). Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel. Journal of Clinical Oncology. 23(16_suppl). 7017–7017. 13 indexed citations
5.
Ciuleanu, T-E., et al.. (2005). O-157 Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC. Lung Cancer. 49. S54–S54. 16 indexed citations
6.
7.
8.
Postmus, Pieter E., G. Dane, & G. Ross. (2003). 775 Standards of care for patients with small cell lung cancer (SCLC): a survey of clinical practice within the European Union (EU). European Journal of Cancer Supplements. 1(5). S233–S233. 1 indexed citations
9.
Ross, G., Stephen Lane, & G. Dane. (2001). Long-term survival in a phase III randomised study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian carcinoma. European Journal of Cancer. 37. S326–S326. 2 indexed citations
10.
Schiller, Joan H., Joachim von Pawel, Paul A. Clarke, et al.. (1997). 41 Preliminary results of a randomized comparative phase III trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC). Lung Cancer. 18. 13–14. 11 indexed citations
11.
Kyritsis, Athanassios P., ES Newlands, Christina Brock, et al.. (1997). Phase II trial of topotecan (T) as a continuous intravenous infusion in patients (PTS) with high grade gliomas. European Journal of Cancer. 33. S203–S203. 6 indexed citations
12.
Dane, G., et al.. (1988). Evidence for homogeneity of thromboxane A2 receptor using structurally different antagonists. European Journal of Pharmacology. 152(3). 311–319. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jane Carleton Breakdown of academic impact, for papers by Coralie Williams Breakdown of academic impact, for papers by IE Smith Breakdown of academic impact, for papers by M K Bowling Breakdown of academic impact, for papers by Peter Mu‐Hsin Chang Breakdown of academic impact, for papers by Karen Zempolich Breakdown of academic impact, for papers by Seng Chuan Tang Breakdown of academic impact, for papers by Fathima Sheriff Breakdown of academic impact, for papers by Jiamao Lin Breakdown of academic impact, for papers by Raquel Torres
Rankless by CCL
2026